Recent advancements in medical therapy for heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection ...
Closed Loop Medicine Debuts WeDosify in US to Personalize GLP-1 Dosing and Improve Patient Adherence
The platform enables clinicians to tailor GLP-1 titration at scale, aiming to reduce discontinuation rates and improve long-term outcomes for patients undergoing obesity treatment.
MindRank AI Ltd., a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced the ...
In a groundbreaking development, Pfizer's strategic investment of $4.9 billion in obesity startup Metsera is yielding promising results. The latest Phase IIb trial of MET-097i, a glucagon-like peptide ...
Clinical Trials Arena on MSN
Pfizer’s obesity bet shows 14.1% weight loss in Phase IIb trial
"Pfizer’s obesity bet shows 14.1% weight loss in Phase IIb trial" was originally created and published by Clinical Trials ...
@2024 - All Right Reserved.
Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing for Metastatic Non–Small-Cell Lung Cancer in a Large Community Oncology Practice Patients receiving taxanes are at risk for ...
A range of production processes frequently employ acid mixtures comprised of two or three acids; for example, nitric acids, sulfuric acids and hydrochloric acids. In order to use these acids safely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback